Issue |
Analusis
Volume 27, Number 6, July/August 1999
Metrology
|
|
---|---|---|
Page(s) | 523 - 532 | |
Section | Original articles | |
DOI | https://doi.org/10.1051/analusis:1999129 |
DOI: 10.1051/analusis:1999129
Identification of N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine (MBDB), an homologue derivative of "ecstasy"
Ph. Baudot1, A. Vicherat2, M.-L. Viriot1 and M.-C. Carré1, 31 Département de Chimie Physique des Réactions (DCPR), UMR 7630 CNRS-INPL, École Nationale Supérieure des Industries Chimiques (ENSIC), Institut National Polytechnique de Lorraine (INPL), 1 rue Grandville, BP. 451, 54001 Nancy Cedex, France
2 Service de RMN, ENSIC-INPL, France
3 INSERM, Plateau de Brabois, 54505 Vandoeuvre-les-Nancy, France
(Received December 29, 1998; revised March 03, 1999; accepted March 03, 1999. )
Abstract
Some of the various N-substituted derivatives of the MDA have become popular drugs of abuse (MDMA, MDEA) in Europe and in France. With the increasing seizures of
MBDB, [N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine] a new homologue of MDMA and MDEA, forensic analysis of these controlled substances requires the use of powerful
techniques to characterize them. Analysis by either high performance liquid chromatography (HPLC) or capillary gas chromatography (CGC) allows the separation of MDMA, MDEA,
MBDB and EBDB. The isomers MDEA and MBDB are best differentiated by either nuclear magnetic resonance spectroscopy (1H-NMR) or the combination of mass spectra (MS) and
retention time (CGC). These techniques were successfully applied to seized tablets.
Key words: MBDB / EBDB / DRUGS / HPLC / CGC-MS / NMR / tablets.
© EDP Sciences, Wiley-VCH 1999